Confo to receive up front & is eligible to receive development and commercial milestones of ~$182.80M along with royalties. The companies collaborated for the discovery and development of small molecule agonists against an undisclosed target associated with CNS diseases
Daiichi Sankyo get an exclusive option to acquire an exclusive license globally for the resulting compounds and advance them toward clinical development and commercialization. Confo will be responsible for the discovery process to generate lead series of small molecule compounds using the GPCR platform
The partnership will make use of Confo’s capabilities and platform to investigate a previously unreachable GPCR target in an area of high unmet medical need
Ref: Businesswire | Image: Confo
Related News:- Confo Therapeutics Entered into a Global License Agreement with Eli Lilly for CFTX-1554
